Trial Profile
A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of REGN1033 Produced From Two Different Cell Lines in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2017
Price :
$35
*
At a glance
- Drugs Trevogrumab (Primary)
- Indications Muscular atrophy
- Focus Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 13 Oct 2016 Status changed from recruiting to completed.
- 20 Apr 2016 New trial record